Steven Cohen Syndax Pharmaceuticals Inc Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 4,008,700 shares of SNDX stock, worth $42.3 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
4,008,700
Previous 1,915,736
109.25%
Holding current value
$42.3 Million
Previous $25.3 Million
94.53%
% of portfolio
0.12%
Previous 0.06%
Shares
22 transactions
Others Institutions Holding SNDX
# of Institutions
240Shares Held
101MCall Options Held
1.36MPut Options Held
618K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$89.8 Million8.82% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$83.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.87MShares$51.3 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.21MShares$44.4 Million5.73% of portfolio
-
State Street Corp Boston, MA3.97MShares$41.9 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $596M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...